Exagen (XGN) Shares Outstanding (Weighted Average) (2018 - 2026)

Exagen has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $23.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 28.55% year-over-year to $23.9 million; the trailing twelve-month figure through Mar 2026 stood at $23.9 million (up 28.55% YoY), and the FY2025 full-year result was $21.6 million, up 18.43% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $23.9 million, up from $21.6 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $23.9 million in Q1 2026, with the low at $1.1 million in Q3 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $14.4 million across 5 years, with a median of $17.7 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) soared 3881.1% — and 2024, when it sank 93.61%.
• Exagen's Shares Outstanding (Weighted Average) stood at $17.1 million in 2022, then increased by 3.5% to $17.7 million in 2023, then gained by 2.96% to $18.2 million in 2024, then advanced by 18.43% to $21.6 million in 2025, then increased by 10.65% to $23.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $23.9 million (Q1 2026), $21.6 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.